What is SAB Biotherapeutics Inc (SABS) stock price today?

SAB Biotherapeutics Inc (SABS) currently trades at $3.74 per share. The stock has a market capitalization of $248.07M and a P/E ratio of —x.

Is SABS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, SAB Biotherapeutics Inc has a Smart Value Score of 36/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is SAB Biotherapeutics Inc's revenue and earnings?

SAB Biotherapeutics Inc has trailing twelve-month (TTM) revenue of $114700.00 with profit margins of 0.00%. Earnings per share (EPS) is $-0.79.

SABS

SAB Biotherapeutics Inc

NASDAQ: SABS · HEALTHCARE · BIOTECHNOLOGY

$3.74

+7.47% today

Updated 2026-04-30

Market cap

$248.07M

P/E ratio

—

P/S ratio

2.96x

EPS (TTM)

$-0.79

Dividend yield

—

52W range

$2 – $5

Volume

0.6M

Market cap

$248.07M

P/E ratio

—

P/S ratio

2.96x

EPS (TTM)

$-0.79

Dividend yield

—

52W range

$2 – $5

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

3.0

Growth

5.0

Quality

C+

4.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$9.50

+154.01%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-17.71M

- Revenue declining -62.40% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$23.90M	$2.24M	$1.32M	$0.00	$114700.00
Net income	$-18.74M	$-42.19M	$-34.11M	$13.27M	$-16.86M
EPS	—	—	—	—	$-0.79
Free cash flow	$-25.63M	$-25.32M	$-34.63M	$-45.71M	$-17.71M
Profit margin	-78.40%	-1,884.50%	-2,579.03%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SABS	$248.07M	36	3.0	4.5	5.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

SAB Biotherapeutics Inc trades at $3.74. Our Smart Value Score of 36/100 indicates the stock is weak. TTM revenue stands at $114700.00.

Frequently asked questions

What is SAB Biotherapeutics Inc's stock price?

SAB Biotherapeutics Inc (SABS) trades at $3.74.

Is SAB Biotherapeutics Inc overvalued?

Smart Value Score 36/100 (Grade D, Sell).

What is the price target of SAB Biotherapeutics Inc (SABS)?

The analyst target price is $9.50, representing +154.0% upside from the current price of $3.74.

What is SAB Biotherapeutics Inc's revenue?

TTM revenue is $114700.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio2.96x

ROE15.00%

Beta0.61

50D MA$3.87

200D MA$3.27

Shares out0.07B

Float0.03B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SABS vs LLY →SABS vs JNJ →SABS vs ABBV →Stock screener →